Shifting Patterns in Sourcing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Shifting Patterns in Sourcing
The pharmaceutical supply chain lengthens as generic drug manufacturers build production platforms offshore and CMOs position in India and China to meet demand for lower-cost production.


Pharmaceutical Technology


The pharmaceutical supply chain: DCAT Week




The pharmaceutical supply chain will be the focus later this month at a series of educational sessions held Mar. 19–22 during the Drug, Chemical, and Associated Technologies Association's (DCAT, Robbinsville, NJ, http://www.dcat.org/) annual program in New York City.

DCAT is a 365-member company association that consists of firms that manufacture, distribute, or provide services to the pharmaceutical, chemical, nutritional, and related industries. Its members include professionals engaged in sourcing, procurement, and supply-chain management from large- and medium-sized innovator pharmaceutical companies, generic drug companies, and consumer healthcare companies. On the supply side, DCAT's membership consists of manufacturers and distributors of active pharmaceutical ingredients, intermediates, other pharmaceutical ingredients, formulation services, pharmaceutical packaging, and related services.

On Monday Mar. 19, DCAT will hold its Fifth Annual International Business Forum: Pharmaceutical Manufacturing: The Next Wave of Transformation, which will examine the latest changes in the pharmaceutical supply chain, including input from Charles M. Shafran, vice-president, strategic planning from Pfizer Global Manufacturing, who will discuss divestiture of pharmaceutical manufacturing assets.

On Tuesday Mar. 20, DCAT will hold its Business Perspective Program, which will explain how the pharmaceutical industry is working with the Business for Social Responsibility (San Francisco, CA, http://www.bsr.org/), a nonprofit business membership and advisory organization, to develop the Pharmaceutical Industry Principles for Responsible Supply Chain Management.

Also on Mar. 20, DCAT will hold a session addressing the evolving regulatory environment for chemical registration in China and its impact on the supply chain.

Other programs designed for DCAT member companies include sessions on over-the-counter drug packaging and human resource development for the pharmaceutical chemical industry.

On Mar. 21, DCAT will present the IMS Health (Fairfield, CT, http://www.imshealth.com/) annual pharmaceutical outlook. The DCAT Annual Dinner will be held Thursday, Mar. 22. This annual black-tie event this year will feature Sir Richard Branson, founder and chairman of the Virgin Group as the guest speaker.

Full details about the programs may be found at http://www.dcat.org/2007_DCAT_Week/schedule.php.

References

1. P. Van Arnum, "The Changing Fortunes of APIs," Pharm. Technol. 31 (1), 52–58 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here